Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amtenofovir for chronic hepatitis B with normal ALT
ChiCTR2100053602Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir amibufenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Proportion of subjects with serum HBV DNA <20 IU/mL. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
tenofovir amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100053602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053602.